ClinicalTrials.gg

Program

DNV001

A development code. Also written as “DNV001 Injection”.

Its studies are mostly in Hypercholesterolemia, led by Hangzhou Dinovate Biotech.

Furthest: phase 2, since Dec 14, 20251 company-led study, 1 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou Dinovate Biotech11 open or runningphase 2since Dec 14, 2025Dec 14, 2025Jun 30, 2027phase 2 · NCT07391722

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 14, 2025First study: phase 2 study in HypercholesterolemiaFirst studyNCT07391722 · 120 planned

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in HypercholesterolemiaNCT07391722

TargetBeta

PCSK9 →read by rule
“DNV001 is a human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), administered as a sterile solution for subcutaneous injection.”study text, by rule · the study

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07391722Hypercholesterolemia2Not yet recruitingJun 30, 2027120

How it is read

Names in the registry

  • “DNV001 Injection”, 1 entry

Codes read as this program: DNV001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.